185122-75-2

Basic information

• Product Name: 5H-CYCLOPENTA[B]PYRIDIN-7-AMINE, 6,7-DIHYDRO-
• Synonyms: 5H-CYCLOPENTA[B]PYRIDIN-7-AMINE, 6,7-DIHYDRO-;5H-Cyclopenta[b]pyridin-7-amino,6,7-dihydro-;5H-Cyclopenta[b]pyridin-7-amine,6,7-dihydro-(9CI);6,7-Dihydro-5H-cyclopenta[b]pyridin-7-amine;6,7-Dihydro-5H-[1]pyrindin-7-ylamine
• CAS NO: 185122-75-2
• Molecular Formula: C₈H₁₀N₂
• Molecular Weight: 134.18
• Product Categories: PYRIDINE;Pyridine Derivertives
• Mol File: 185122-75-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 255.243oC at 760 mmHg
• Flash Point: 131.856oC
• Appearance: /
• Density: 1.125g/cm3
• Vapor Pressure: 0.016mmHg at 25°C
• Refractive Index: 1.586
• CAS DataBase Reference: 5H-CYCLOPENTA[B]PYRIDIN-7-AMINE, 6,7-DIHYDRO-(CAS DataBase Reference)
• NIST Chemistry Reference: 5H-CYCLOPENTA[B]PYRIDIN-7-AMINE, 6,7-DIHYDRO-(185122-75-2)
• EPA Substance Registry System: 5H-CYCLOPENTA[B]PYRIDIN-7-AMINE, 6,7-DIHYDRO-(185122-75-2)

Safety Data

• Hazardous Substances Data: 185122-75-2(Hazardous Substances Data)

Usage

Description

5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydrois a heterocyclic amine belonging to the cyclopenta[b]pyridine derivatives class. It features a cyclopentane ring fused to a pyridine ring, with a primary amine group attached at the seventh carbon atom. 5H-CYCLOPENTA[B]PYRIDIN-7-AMINE, 6,7-DIHYDROmay have potential pharmaceutical applications due to its diverse biological activities, such as antifungal, antiviral, and anticancer properties. Its dihydro form indicates a reduced state, which may influence its reactivity and biological activity. This chemical compound holds promise as a valuable tool in drug discovery, development, and medicinal chemistry research.

Uses

Used in Pharmaceutical Applications:
5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydrois used as a potential pharmaceutical agent for its diverse biological activities, including antifungal, antiviral, and anticancer properties. Its heterocyclic amine structure contributes to its therapeutic potential in various medical applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydroserves as a building block for the synthesis of more complex chemical compounds. Its unique structure and reduced state may offer new avenues for the development of novel therapeutic agents and contribute to the advancement of drug discovery.
Used in Drug Synthesis:
5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydrois used as a key intermediate in the synthesis of various pharmaceutical compounds. Its heterocyclic nature and functional groups provide opportunities for further chemical modifications, enabling the creation of new drugs with improved efficacy and selectivity.
Used in Drug Discovery:
As a chemical compound with potential pharmaceutical applications, 5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydrois utilized in drug discovery processes. Its diverse biological activities and unique structural features make it a promising candidate for the development of new therapeutic agents targeting various diseases and conditions.
Used in Chemical Research:
5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydrois employed in chemical research to explore its reactivity, stability, and potential interactions with other molecules. Understanding its properties and behavior can contribute to the advancement of chemical knowledge and the development of new synthetic methods and applications.

InChI:InChI=1/C8H10N2/c9-7-4-3-6-2-1-5-10-8(6)7/h1-2,5,7H,3-4,9H2

Upstream product

• 1071727-78-0 5,6-dihydro-[1]pyrindin-7-one O-methyl-oxime 

Downstream Products

• 1228571-16-1 (S)-5H,6H,7H-cyclopenta[b]pyridin-7-amine 
• 298181-96-1 C₂₈H₂₇N₅O₄S 
• 1228571-16-1 (R)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine 

Relevant articles and documents

Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication

The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure-activity relationship (SAR) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N′-((1H-benzo[d]imidazol-2-yl)methyl)- N′-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 μM. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS

Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

Substituted aryl 1,4-pyrazine derivatives

Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.